$SBFM

Sunshine Biopharma Inc.

Insider trades
2
0
1

No SEC Form 4 filings for $SBFM in the last 30 days.

See all $SBFM insider activity →
Med

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Sunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.

K1.1 mRNA suppressed tumors alone in at least two liver-cancer mouse models

Sunshine Biopharma (SBFM) reported that its K1.1 mRNA lipid nanoparticle showed tumor-suppressing activity in liver cancer mouse models. The company plans to test the mRNA with a cancer vaccine in non-small cell lung cancer (NSCLC). SBFM's stock declined 6.14% following the announcement, trading at $1.07 with heavy volume.

EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug

Sunshine Biopharma (SBFM) received Canadian approval for its generic Enalapril tablets, entering the antihypertensive drug market. The company plans to launch 12 more drugs in 2026 and expects shipments by year-end. The global antihypertensive market is projected to grow to $37.24B by 2034. SBFM shares rose 1.79% in premarket trading.

SBFM sentiment & insider activity

Over the past 7 days, alphai's AI scored 3 news stories mentioning SBFM (Sunshine Biopharma Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.

Recent SBFM coverage spans regulation, technology and corporate actions.

What's driving SBFM

  • Positive preclinical data may de‑risk the program and attract partnership or financing interest.

    accessnewswire.com · Aug 26, 2026

  • Preclinical data suggests potential but raises questions on clinical translation; stock reacted negatively.

    stocktitan.net · Aug 26, 2026

  • Approval opens a new revenue stream in the Canadian antihypertensive market.

    yahoo.com · Aug 20, 2026

  • The Canada launch expands SBFM’s marketed generic portfolio and could modestly improve near-term revenue visibility, but the article provides no financial guidance or contract size.

    finanznachrichten.de · Aug 7, 2026

  • Approval enables Canadian market entry for a first-line endometriosis therapy, supporting near-term distribution readiness and potential revenue ramp.

    benzinga.com · Aug 4, 2026

alphai scores every news story that mentions SBFM with an AI model for sentiment and relevance, and aggregates insider trades from Sunshine Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SBFM

Score
$SBFMMedAI 8/10

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Sunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.

Sunshine Biopharma Inc.: Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it launched generic amoxicillin in Canada and began shipping to pharmacies this week in multiple dosages and strengths. The company cited 2025 global amoxicillin sales of about $4.9B, projected to reach about $6.4B by 2031. It also noted its Canadian portfolio includes 60 drugs on market.

$SBFMMedAI 8/10

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Sunshine Bi

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval to market its 2mg generic Dienogest tablets for first-line treatment of endometriosis-related pelvic pain. Distribution will be handled by its wholly owned Canadian subsidiary, Nora Pharma. The company expects retail pharmacy shipments by end-2026. Shares rose 6.84% premarket to $1.25.

$SBFMMedAI 8/10

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval for its 2mg generic Dienogest tablets for first-line treatment of pelvic pain from endometriosis. Distribution will be through its wholly owned Nora Pharma. Management expects retail shipments by end-2026. The article also notes a June one-for-ten reverse split and recent approval for generic ondansetron.

$SBFMMed

Sunshine Biopharma Inc. (SBFM): Entry into a Material Definitive Agreement

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 sunshine_ex1001.htm AT-THE-MARKET ISSUANCE SALES AGREEMENT, Exhibit 10.1 AT-THE-MARKET ISSUANCE SALES AGREEMENT July 20, 2026 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma Inc., a Colorado corpora

$SBFMLow

Sunshine Biopharma Inc. (SBFM): Entry into a Material Definitive Agreement

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 sunshine_ex1001.htm RELEASE AGREEMENT Exhibit 10.1 AGREEMENT OF TRANSACTION AND MUTUAL RELEASE Between: Malek Chamoun , domiciled at XXXXXXXXXX (hereinafter “ Chamoun ”) And: Sunshine Biopharma inc ., having a place of business at 1565 Lionel-Boulet boulevard, Varennes,

Related tickers